ZURICH, April 21 The Swiss blue-chip SMI
was seen opening 0.1 percent higher at 8,563 points on Friday,
according to premarket indications by bank Julius Baer
The following are some of the main factors expected to
affect Swiss stocks:
* Banking software supplier Temenos confirmed its
full-year guidance after growing revenues by 13 percent in the
first quarter of 2017, according to non-IFRS reporting standards
and a constant-currency basis, and earnings before interest and
tax 15 percent to 27.3 million Swiss francs.
* SHL Telemedicine said its board had resolved
today to appoint Yoav Rubinstein as an interim acting CEO and
Yossi Vadnagra as interim acting CFO.
* Basilea Pharmaceutica said it has reached
agreement with the U.S. Food and Drug Administration (FDA) on
Special Protocol Assessments (SPAs) for its two planned phase 3
clinical studies of Basilea's antibiotic ceftobiprole.
* Dottikon Holding said it's ceasing its
third-party solvent recycling business in the second half of
2017. Extraordinary effects will bring down full-year 2016/17
results by around 5 million francs, the group said, but Dottikon
still expects an increase in net sales and net income
year-on-year for the year ended March 31.
* BB Biotech expects significant cash in the second
quarter from Johnson & Johnson's acquisition of Actelion
. The biotech investment company reported bottom-line
profit of 375 million francs in the first quarter of 2017 as its
portfolio generated returns of 7.7 percent in francs and 7.1
percent in euros.
* Panalpina Welttransport Holding posted
first-quarter consolidated profit of 12.4 million francs
compared to 17.3 million francs a year earlier.
* Inficon Holding AG said first-quarter operating
income more than doubled to $17.8 million. It maintained its
guidance for the full year 2017, expecting sales of over $320
million and an operating income margin exceeding 17 percent.
(Reporting by Zurich newsroom)